Related Experiment Video
Updated: Dec 5, 2025
07:45
Author Spotlight: Standardizing Mouse In Vivo PET Imaging with Body Conforming Molds and Automated Analysis
Published on: October 25, 2024
642
Aβ-PET pathology accumulation index: Ready for the clinic?
Geoffrey A Kerchner1, Massimo Filippi2
1From Product Development Neuroscience (G.A.K.), F. Hoffmann-La Roche, Ltd, Basel, Switzerland; Neurology and Neurophysiology Units (M.F.) and Neuroimaging Research Unit (M.F.), Institute of Experimental Neurology, Division of Neuroscience, IRCCS San Raffaele Scientific Institute; and Vita-Salute San Raffaele University (M.F.), Milan, Italy. geoff.kerchner@roche.com.
Neurology
|October 20, 2020
Summary
No abstract available in PubMed .
Related Concept Videos
01:28Preclinical Development: Overview
5.6K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.6K
01:11Clinical Trials: Overview
4.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K